Apr 29, 2019
Investigational Agents in Ulcerative Colitis: IL-12 and IL-23 InhibitorsInflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patients still suffer poor quality of life and suboptimal outcomes. Therefore, safer and more effective UC therapies are needed.
In this CME podcast activity, Dr. Peter Higgins and Dr. David Rubin will discuss investigational interleukin-12 and interleukin-23 inhibitors for treating UC.
For the transcript of this podcast, click here.
To obtain CME credit, click here